Abstract LB366: Fianlimab + cemiplimab in patients (pts) with advanced (adv) melanoma (Mel): Subgroup analyses by blinded independent central review (BICR)
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Meredith McKean, Amy M. Weise, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Janice Mehnert, John M. Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda L. Yushak, Jayakumar Mani, Fang Fang, Shuquan Chen, Jingxiao Chen, Laura Brennan, JuAn Wang, Israel Lowy, Mark Salvati, Matthew G. Fury, Karl D. Lewis, Omid Hamid
Institutions: Sarah Cannon, Henry Ford Hospital, South Texas Accelerated Research Therapeutics, St. Vincent's University Hospital, Orlando Health, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Medical University of South Carolina, MUSC Hollings Cancer Center, California Pacific Medical Center, Emory University, Regeneron (United States), Angeles Clinic and Research Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409821084